Online inquiry

IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5806MR)

This product GTTS-WQ5806MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Kidney transplant rejection, Psoriasis, Myasthenia Gravis (MG) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5806MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5012MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA c4G7-N
GTTS-WQ2668MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 655
GTTS-WQ1620MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ5845MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ7391MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ9828MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ13017MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ3144MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA APT070
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW